Korea Spotlight: Eutilex readying first U.S. trial as cancer company aims for global stage   

Eutilex hopes data from an upcoming Phase I trial of its anti-4-1BB antibody will help land the South Korean biotech a global licensing partner for the compound, VP and Head of Open Innovation and Global Strategy So Heui Choe told BioCentury.

The trial, which will be the first run in the U.S. by Eutilex Co. Ltd. (KOSDAQ:263050), will assess EU101 and begin in May in up to 80 patients with colon cancer and other solid tumors. FDA accepted an IND for the study on Jan. 14...